Physician profile
Marc R Happe
NPI 1164580874
$5,796.63
in general payments reported to CMS, 2019-2025
25 companies · $591 in 2025
The $591 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $2,661 · 2021: $251 · 2022: $608 · 2023: $454 · 2024: $941 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,952 · Education: $32.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,952.47 |
| Education | $32.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $2,799.18 | 2019-2020 | |
| Abbvie INC. | $1,232.48 | 2019-2025 | |
| Janssen Biotech, INC. | $851.44 | 2020-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $165.18 | 2024-2025 | Resmetirom, Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $136.61 | 2024-2025 | Eohilia, Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.58 | 2019-2024 | Xifaxan |
| Fujifilm Healthcare Americas Corporation | $101.11 | 2022 | |
| Medtronic, INC. | $65.49 | 2021-2025 | Interstim |
| Genzyme Corporation | $49.05 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $43.87 | 2019-2024 | |
| Shire North American Group INC | $33.37 | 2019 | |
| Celltrion USA INC. | $32.43 | 2024 | Zymfentra |
| Avanos Medical | $25.74 | 2019 | |
| Ardelyx, INC. | $23.89 | 2024 | Ibsrela |
| Gilead Sciences, INC. | $22.69 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $22.17 | 2022 | |
| Phathom Pharmaceuticals, INC. | $20.63 | 2025 | Voquezna |
| Aimmune Therapeutics, INC. | $17.69 | 2024 | |
| Celgene Corporation | $13.68 | 2022 | |
| Pfizer INC. | $11.35 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Happe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.